Laura R Marks1, Satish Munigala1, David K Warren1, David B Liss2,3, Stephen Y Liang1,2, Evan S Schwarz2,3, Michael J Durkin1. 1. Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. 2. Division of Emergency Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. 3. Section of Medical Toxicology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Abstract
BACKGROUND: Patients with opioid use disorder (OUD) are frequently admitted for invasive infections. Medications for OUD (MOUD) may improve outcomes in hospitalized patients. METHODS: In this retrospective cohort of 220 admissions to a tertiary care center for invasive infections due to OUD, we compared 4 MOUD treatment strategies: methadone, buprenorphine, methadone taper for detoxification, and no medication to determine whether there were differences in parenteral antibiotic completion and readmission rates. RESULTS: The MOUDs were associated with increased completion of parenteral antimicrobial therapy (64.08% vs 46.15%; odds ratio [OR] = 2.08; 95% CI, 1.23-3.61). On multivariate analysis, use of MOUD maintenance with either buprenorphine (OR = 0.38; 95% CI, .17-.85) or methadone maintenance (OR = 0.43; 95% CI, .20-.94) and continuation of MOUD on discharge (OR = 0.35; 95% CI, .18-.67) was associated with lower 90-day readmissions. In contrast, use of methadone for detoxification followed by tapering of the medication without continuation on discharge was not associated with decreased readmissions (OR = 1.87; 95% CI, .62-5.10). CONCLUSIONS: Long-term MOUDs, regardless of selection, are an integral component of care in patients hospitalized with OUD-related infections. Patients with OUD should have arrangements made for MOUDs to be continued after discharge, and MOUDs should not be discontinued before discharge.
BACKGROUND: Patients with opioid use disorder (OUD) are frequently admitted for invasive infections. Medications for OUD (MOUD) may improve outcomes in hospitalized patients. METHODS: In this retrospective cohort of 220 admissions to a tertiary care center for invasive infections due to OUD, we compared 4 MOUD treatment strategies: methadone, buprenorphine, methadone taper for detoxification, and no medication to determine whether there were differences in parenteral antibiotic completion and readmission rates. RESULTS: The MOUDs were associated with increased completion of parenteral antimicrobial therapy (64.08% vs 46.15%; odds ratio [OR] = 2.08; 95% CI, 1.23-3.61). On multivariate analysis, use of MOUD maintenance with either buprenorphine (OR = 0.38; 95% CI, .17-.85) or methadone maintenance (OR = 0.43; 95% CI, .20-.94) and continuation of MOUD on discharge (OR = 0.35; 95% CI, .18-.67) was associated with lower 90-day readmissions. In contrast, use of methadone for detoxification followed by tapering of the medication without continuation on discharge was not associated with decreased readmissions (OR = 1.87; 95% CI, .62-5.10). CONCLUSIONS: Long-term MOUDs, regardless of selection, are an integral component of care in patients hospitalized with OUD-related infections. Patients with OUD should have arrangements made for MOUDs to be continued after discharge, and MOUDs should not be discontinued before discharge.
Authors: James D Wines; Richard Saitz; Nicholas J Horton; Christine Lloyd-Travaglini; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2007-02-05 Impact factor: 4.492
Authors: Catherine Anne Fullerton; Meelee Kim; Cindy Parks Thomas; D Russell Lyman; Leslie B Montejano; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon Journal: Psychiatr Serv Date: 2014-02-01 Impact factor: 3.084
Authors: Nathanial S Nolan; Emily Gleason; Laura R Marks; Tracey Habrock-Bach; Stephen Y Liang; Michael J Durkin Journal: Front Psychiatry Date: 2022-06-21 Impact factor: 5.435
Authors: Thomas D Brothers; Dan Lewer; Nicola Jones; Samantha Colledge-Frisby; Michael Farrell; Matthew Hickman; Duncan Webster; Andrew Hayward; Louisa Degenhardt Journal: PLoS Med Date: 2022-07-19 Impact factor: 11.613
Authors: Laura R Marks; Juan J Calix; John A Wildenthal; Meghan A Wallace; Sanjam S Sawhney; Eric M Ransom; Michael J Durkin; Jeffrey P Henderson; Carey-Ann D Burnham; Gautam Dantas Journal: Commun Med (Lond) Date: 2021-11-30
Authors: Thomas D Brothers; Kimiko Mosseler; Susan Kirkland; Patti Melanson; Lisa Barrett; Duncan Webster Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240
Authors: David P Serota; Hansel E Tookes; Belén Hervera; Babley M Gayle; Cara R Roeck; Edward Suarez; David W Forrest; Michael A Kolber; Tyler S Bartholomew; Allan E Rodriguez; Susanne Doblecki-Lewis Journal: Ann Med Date: 2021-12 Impact factor: 5.348